CIK 0001593899 · Non-accelerated filer<br>Smaller reporting company
Atea Pharmaceuticals, Inc.
Sign in to watch- Ticker
- AVIR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- MA
- Entity type
- operating
- EIN
- 460574869
- Phone
- (857) 284-8891
- Business address
- 225 FRANKLIN STREET, SUITE 2100, BOSTON, MA, 02110
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-01-31 | Hammond Janet MJ Chief Development Officer | Option exercise | +46,800 | 49,391 | ||
| 2024-01-31 | Hammond Janet MJ Chief Development Officer | Option exercise · Restricted Stock Units | −46,800 | 93,600 | ||
| 2024-01-31 | Hammond Janet MJ Chief Development Officer | Grant or award · Stock Option (Right to Buy) | +225,200 | 225,200 | ||
| 2023-06-16 | BERGER FRANKLIN M Director | Grant or award · Restricted Stock Units | +33,150 | 33,150 | ||
| 2023-06-16 | BERGER FRANKLIN M Director | Grant or award · Stock Option (Right to Buy) | +46,750 | 46,750 | ||
| 2023-06-16 | Adams Jerome M. Director | Grant or award · Restricted Stock Units | +33,150 | 33,150 | ||
| 2023-06-16 | Adams Jerome M. Director | Grant or award · Stock Option (Right to Buy) | +46,750 | 46,750 | ||
| 2023-06-16 | Murphy Polly A. Director | Grant or award · Restricted Stock Units | +33,150 | 33,150 | ||
| 2023-06-16 | Murphy Polly A. Director | Grant or award · Stock Option (Right to Buy) | +46,750 | 46,750 | ||
| 2023-06-16 | Polsky Bruce Director | Grant or award · Restricted Stock Units | +33,150 | 33,150 | ||
| 2023-06-16 | Polsky Bruce Director | Grant or award · Stock Option (Right to Buy) | +46,750 | 46,750 | ||
| 2023-06-16 | Duncan Barbara Gayle Director | Grant or award · Restricted Stock Units | +33,150 | 33,150 | ||
| 2023-06-16 | Duncan Barbara Gayle Director | Grant or award · Stock Option (Right to Buy) | +46,750 | 46,750 | ||
| 2023-06-16 | Lucidi Bruno Director | Grant or award · Restricted Stock Units | +33,150 | 33,150 | ||
| 2023-06-16 | Lucidi Bruno Director | Grant or award · Stock Option (Right to Buy) | +46,750 | 46,750 | ||
| 2023-01-31 | Foster Wayne EVP, Chief Accounting Officer | Grant or award · Restricted Stock Units | +100,000 | 100,000 | ||
| 2023-01-31 | Foster Wayne EVP, Chief Accounting Officer | Grant or award · Stock Option (Right to Buy) | +140,000 | 140,000 | ||
| 2023-01-31 | Horga Maria Arantxa Chief Medical Officer | Grant or award · Restricted Stock Units | +124,600 | 124,600 | ||
| 2023-01-31 | Horga Maria Arantxa Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +174,500 | 174,500 | ||
| 2023-01-31 | Sommadossi Jean-Pierre President, CEO, and Chairman | Grant or award · Restricted Stock Units | +520,400 | 520,400 |
Page 10 of 14 · 280 trades